Bleeding with Anticoagulants: ACC Releases Expert Consensus Decision Pathway to Guide Management
Am Fam Physician. 2018 Jul 1;98(1):57-58.
Author disclosure: No relevant financial affiliations.
Key Points for Practice
• One or more of the following factors qualify bleeding as a major event: critical site location, hemodynamic instability, bleeding with a decrease in hemoglobin of at least 2 g per dL (20 g per L) or requiring at least 2 units of red blood cells.
• Major and nonmajor bleeding requiring hospitalization, surgery, or transfusion should be controlled and oral anticoagulants discontinued.
• Major life-threatening bleeding or bleeding at a critical site warrant a reversal agent.
From the AFP Editors
More than 6 million persons in the United States are taking anticoagulants for a number of conditions, including venous thromboembolism and atrial fibrillation. These patients have an increased risk of bleeding, which is associated with a greater risk of morbidity and mortality. This Expert Consensus Decision Pathway from the American College of Cardiology (ACC) aims to provide physicians with decision-making assistance for managing bleeding events in patients taking anticoagulants.
Major Bleeding Events
Bleeding is considered to be a major event if it occurs at a critical site, there is accompanying hemodynamic instability, or there is bleeding with a decrease in hemoglobin of at least 2 g per dL (20 g per L) or at least 2 units of red blood cells are transfused. Critical site bleeding includes airway, extremity, intra-abdominal, and intracranial and other central nervous system bleeding; pericardial tamponade; hemothorax; and retroperitoneal hematoma. Symptoms of airway bleeding include hemoptysis, shortness of breath, epistaxis, and hypoxia. Symptoms of extremity bleeding include pain, swelling, pallor, paresthesia, weakness, weak pulse, and decreased range of motion, and can result in compartment syndrome, paralysis, joint damage, and limb loss. Symptoms of intra-abdominal bleeding include pain, distension, hypotension, and tachycardia. Symptoms of intracranial bleeding include intense headache, emesis, and neurologic signs such as reduced level of consciousness, ataxia, aphasia, vertigo, and seizures. Other central nervous system bleeding sites include the eyes (e.g., pain, vision changes or blindness) and spine (e.g., pain, weakness, bowel or bladder dysfunction). Symptoms of pericardial tamponade include shortness of breath, tachypnea, hypotension, jugular venous distention, tachycardia, and muffled heart sounds. Symptoms of hemothorax include tachypnea, tachycardia, and hypotension. Symptoms of retroperitoneal hematoma include pain, tachycardia, and hypotension, and a hematoma can result in femoral neuropathy.
When a patient presents with bleeding or requires an emergency procedure, laboratory measurement of anticoagulant activity can aid in the assessment. A prothrombin time and activated partial thromboplastin time should be ordered. If specialized assays are available, these tests can include dilute thrombin time, ecarin clotting time, and ecarin chromogenic assay for patients on dabigatran (Pradaxa); and a chromogenic anti-factor Xa test for patients on apixaban (Eliquis), edoxaban (Savaysa), or rivaroxaban (Xarelto).
When specialized assays are not available, thrombin time and activated partial thromboplastin time can generally assess drug levels in patients taking dabigatran. For patients on apixaban, edoxaban, or rivaroxaban, prothrombin time is used to assess therapy.
Major and nonmajor bleeding requiring hospitalization, surgery, or transfusion should be controlled and oral anticoagulants discontinued. In patients with nonmajor bleeding, temporary discontinuation of anticoagulants may be necessary. Factors affecting this decision include whether the anticoagulation is therapeutic or supratherapeutic, upcoming invasive procedures, the patient's underlying bleeding risk, concern for slow bleed or need for further evaluation of clinical impact of bleed, presence of anemia requiring transfusion, and medical comorbidities. Collaborative evaluation of future bleeding risk vs. benefit of anticoagulation therapy in patients with ongoing thrombotic risk is needed before resuming therapy. A delay in resuming therapy is recommended if the bleeding occurred at a critical site, the patient is at increased risk of death or disability from rebleeding, an invasive procedure is needed, or the patient prefers not to resume therapy.
Using Reversal Agents
In patients with a major bleeding event, even if it is not at a critical site or life threatening, local therapy, manual compression, and supportive care should be provided. Any antiplatelet agents should be discontinued, and those receiving vitamin K antagonists should also be given intravenous vitamin K. Any comorbidities that could contribute to bleeding should be managed, and surgical management of bleeding should be considered. Those with major life-threatening bleeding or bleeding at a critical site, including patients with an uncontrollable major bleeding event, should also receive a reversal agent. Available agents include 4-factor prothrombin complex concentrate for warfarin (Coumadin), dabigatran (second line), apixaban, edoxaban, and rivaroxaban; activated prothrombin complex concentrate as a second-line option for dabigatran, apixaban, edoxaban, and rivaroxaban; idarucizumab (Praxbind) for dabigatran; and plasma for warfarin if 4-factor prothrombin complex concentrate is not available. [corrected]
Patients with nonmajor bleeding that requires hospitalization, surgery, or transfusion and who are on vitamin K antagonists should receive oral or intravenous vitamin K. Those not on vitamin K antagonists should not receive a reversal agent. Local therapy, manual compression, and supportive care should be provided; antiplatelets discontinued (if appropriate); contributing comorbidities managed; and surgery considered. For all other nonmajor bleeding, anticoagulants may be continued if clinically indicated; however, these patients should also receive local therapy and manual compression. Antiplatelet treatment should be reassessed to determine if it should be discontinued, comorbidities should be managed, and anticoagulant dosing reevaluated. [corrected]
Guideline source: American College of Cardiology
Evidence rating system used? No
Systematic literature search described? No
Guideline developed by participants without relevant financial ties to industry? No
Recommendations based on patient-oriented outcomes? Yes
Published source: J Am Coll Cardiol. December 19, 2017;70(24):3042–3067
Available at: http://www.onlinejacc.org/content/70/24/3042
Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.
This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.
A collection of Practice Guidelines published in AFP is available at https://www.aafp.org/afp/practguide.
Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Aug 15, 2019
Access the latest issue of American Family Physician